By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Polaryx Therapeutics, Inc. insiders have been one-way buyers this past year: two people put roughly $368,000 into the stock and nobody sold on the open market.
Mstone Partners Healthcare Ltd (CEO) made the biggest buy, worth around $360,000. Notably, at least one C-suite executive was among the buyers.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters. On the institutional side, 13 funds reported holding PLYX at the end of Q2 2026, and more funds sold than bought.
Are insiders buying or selling PLYX stock?
In the last 12 months Polaryx Therapeutics, Inc. insiders made open-market purchases worth about $368,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in PLYX?
The most recent open-market insider trade in PLYX was filed on 2026-05-28.
How many institutions own PLYX?
13 investment managers reported holding PLYX in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded PLYX?
No congressional trades in PLYX were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).